Form 8-K - Current report:
SEC Accession No. 0001104659-25-067597
Filing Date
2025-07-14
Accepted
2025-07-14 08:00:47
Documents
15
Period of Report
2025-07-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2520238d1_8k.htm   iXBRL 8-K 57740
2 EXHIBIT 2.1 tm2520238d1_ex2-1.htm EX-2.1 973016
3 EXHIBIT 10.1 tm2520238d1_ex10-1.htm EX-10.1 34777
4 EXHIBIT 99.1 tm2520238d1_ex99-1.htm EX-99.1 28878
  Complete submission text file 0001104659-25-067597.txt   1465764

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA epix-20250713.xsd EX-101.SCH 3020
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE epix-20250713_lab.xml EX-101.LAB 34239
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE epix-20250713_pre.xml EX-101.PRE 22362
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2520238d1_8k_htm.xml XML 3768
Mailing Address SUITE 720 999 WEST BROADWAY VANCOUVER A1 V5Z 1K5
Business Address SUITE 720 999 WEST BROADWAY VANCOUVER A1 V5Z 1K5 (778) 331-0962
ESSA Pharma Inc. (Filer) CIK: 0001633932 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37410 | Film No.: 251120172
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)